Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance in HBV-positive diffuse large B-cell lymphoma
ChiCTR1800017698Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL) and Chronic Hepatitis B (CHB), sponsored by The First Hospital of Jilin University. Primary endpoint: overall survival. Started Aug 2018; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1800017698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017698.